carmustine has been researched along with Lung Diseases in 34 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Lung Diseases: Pathological processes involving any part of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Autologous stem cell transplantation (SCT) with high-dose melphalan (HDM, 200 mg/m2) is the most effective therapy for multiple myeloma." | 9.12 | Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation. ( Comenzo, RL; Dhodapkar, M; Filippa, D; Fleisher, M; Hassoun, H; Kewalramani, T; Klimek, V; Nimer, SD; Reich, L; Teruya-Feldstein, J, 2006) |
| "Carmustine (BCNU) was employed as the only chemotherapeutic agent in a Radiation Therapy Oncology Group multimodality study comparing misonidazole-radiosensitized radiation therapy to conventional radiation therapy in 318 patients with malignant glioma." | 9.06 | Pulmonary toxicity of carmustine in patients treated for malignant glioma. ( Diener-West, M; Nelson, DF; Pakuris, E; Weinstein, AS, 1986) |
| "Autologous stem cell transplantation (SCT) with high-dose melphalan (HDM, 200 mg/m2) is the most effective therapy for multiple myeloma." | 5.12 | Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation. ( Comenzo, RL; Dhodapkar, M; Filippa, D; Fleisher, M; Hassoun, H; Kewalramani, T; Klimek, V; Nimer, SD; Reich, L; Teruya-Feldstein, J, 2006) |
| "Carmustine (BCNU) was employed as the only chemotherapeutic agent in a Radiation Therapy Oncology Group multimodality study comparing misonidazole-radiosensitized radiation therapy to conventional radiation therapy in 318 patients with malignant glioma." | 5.06 | Pulmonary toxicity of carmustine in patients treated for malignant glioma. ( Diener-West, M; Nelson, DF; Pakuris, E; Weinstein, AS, 1986) |
| "Therapy with high-dose cyclophosphamide, cisplatin, and carmustine (BCNU) plus autologous bone marrow transplantation has been extensively studied as treatment for patients with stage II or III breast cancer who have a 70% or greater risk of developing metastatic disease." | 3.68 | Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine. ( Bearman, SI; Dufton, C; Fisher, JH; Jones, RB; Matthes, S; Shpall, EJ; Stemmer, SM; Stephens, JK, 1993) |
| "21 patients with metastatic breast cancer, refractory to conventional agents, were treated with a combination of BCNU, vincristine, mitomycin-C and prednisone given every 4 weeks." | 3.67 | Combination chemotherapy with BCNU, vincristine, mitomycin-C and prednisone in refractory breast carcinoma. A pilot study. ( Anderson, P; DiBella, NJ; Fink, K; Garfield, D; Murphy, J; Speer, J, 1984) |
| "High-dose chemotherapy with BCNU, melphalan, or both, followed by autologous bone marrow transplantation (ABMT) has been reported to produce response rates in excess of 60% in patients with advanced melanoma." | 3.67 | High-dose chemotherapy without autologous bone marrow transplantation in melanoma. ( Aisner, J; Tait, N; Tchekmedyian, NS; Van Echo, D, 1986) |
| "Symptomatic pulmonary disease occurred in 20 per cent of 93 patients with anaplastic gliomas being treated with carmustine (BCNU)." | 3.66 | Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors. ( Aronin, PA; Donohue, JF; Dudka, L; Mahaley, MS; Moore, P; Rudnick, SA; Selker, RG, 1980) |
| "Sixty-five patients with hematological malignancies (25 multiple myeloma, 18 Hodgkin's disease, 22 non-Hodgkin's lymphomas) who received a carmustine-based regimen followed by autologous PBPC transplantation, were studied retrospectively to evaluate the incidence of post-transplant non-infective pulmonary complications (NIPCs), risk factors predictive of NIPCs, and response to steroids." | 2.69 | Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. ( Alessandrino, EP; Bernasconi, C; Bernasconi, P; Caldera, D; Colombo, A; Klersy, C; Malcovati, L; Martinelli, G; Nascimbene, C; Varettoni, M; Vitulo, P; Volpini, E, 2000) |
| "No fatal complications or chronic pulmonary fibrosis was seen." | 2.68 | Pulmonary toxicity of high-dose chemotherapy for breast cancer: a non-invasive approach to diagnosis and treatment. ( Chap, L; Glaspy, J; Levine, M; Lill, M; Norton, L; Shpiner, R, 1997) |
| "Twenty three patients with Hodgkin's disease were treated with BCNU (carmustine), etoposide, and cyclophosphamide at doses of 450-600 mg/m2, 1500-2000 mg/m2, and 120 mg/kg respectively." | 2.38 | High-dose, potentially myeloablative chemotherapy and autologous bone marrow transplantation for patients with advanced Hodgkin's disease. ( Ahmed, T; Arlin, ZA; Ascensao, J; Ciavarella, D; Coleman, M; Engelking, C; Feldman, E; Gingrich, S; Hussain, F; Mittelman, A, 1989) |
| "Diffuse pulmonary diseases seen in patients receiving chemotherapy have a wide variety of etiologies including infection, involvement with the underlying disease, injury from radiation or diagnostic agents, and toxicity from chemotherapeutic drugs." | 2.36 | Review: diagnosis of chemotherapy lung. ( Gamsu, G; Putman, CE; Sostman, HD, 1981) |
| "Simultaneous bilateral spontaneous pneumothorax (SBSP) during high-dose chemotherapy has been described in patients with pulmonary involvement by malignancy, including sarcoma, trophoblastic tumor, non-seminomatous testicular cancer, and non-Hodgkin lymphoma." | 1.36 | Simultaneous bilateral spontaneous pneumothorax following high-dose chemotherapy and bone marrow transplantation for mantle cell lymphoma without evidence of pulmonary disease. ( Schneider, AE; Talmon, GA, 2010) |
| "The incidence of PTS in breast cancer patients treated with a BCNU-containing HDC regimen can be remarkably high." | 1.31 | Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. ( Blume, KG; Cao, TM; Hu, WW; Johnston, LJ; Negrin, RS; Rizk, NW; Shizuru, JA; Stockerl-Goldstein, KE; Taylor, TL; Wong, RM, 2000) |
| "Amiodarone (AM) is an effective antidysrhythmic agent, restricted in use by the development of adverse effects, including potentially fatal AM-induced pulmonary toxicity (AIPT)." | 1.29 | Evaluation of reactive oxygen species involvement in amiodarone pulmonary toxicity in vivo and in vitro. ( Brien, JF; Leeder, RG; Mandin, CC; Massey, TE; Rafeiro, E, 1996) |
| "The occurrence of pulmonary disease associated with long-term BCNU therapy is reported in two patients treated for astrocytoma grade II whose clinical presentations of pulmonary complications and corresponding tissue alterations showed striking differences." | 1.27 | BCNU (1,3-bis-(2-chloroethyl)-1-nitrosurea) lung. Drug-induced pulmonary changes. ( Banerji, B; Greenwald, ES; Koss, LG; Mitsudo, SM, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (50.00) | 18.7374 |
| 1990's | 8 (23.53) | 18.2507 |
| 2000's | 6 (17.65) | 29.6817 |
| 2010's | 3 (8.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schneider, AE | 1 |
| Talmon, GA | 1 |
| Harris, RE | 1 |
| Termuhlen, AM | 1 |
| Smith, LM | 1 |
| Lynch, J | 1 |
| Henry, MM | 1 |
| Perkins, SL | 1 |
| Gross, TG | 1 |
| Warkentin, P | 1 |
| Vlachos, A | 1 |
| Harrison, L | 1 |
| Cairo, MS | 1 |
| Paris, A | 1 |
| Dib, M | 1 |
| Rousselet, MC | 1 |
| Urban, T | 1 |
| Tazi, A | 1 |
| Gagnadoux, F | 1 |
| Rossi, HA | 1 |
| Becker, PS | 1 |
| Emmons, RV | 1 |
| Westervelt, P | 1 |
| Levy, W | 1 |
| Liu, Q | 1 |
| Clark, Y | 1 |
| Ballen, K | 1 |
| Brandes, AA | 1 |
| Tosoni, A | 1 |
| Amistà , P | 1 |
| Nicolardi, L | 1 |
| Grosso, D | 1 |
| Berti, F | 1 |
| Ermani, M | 1 |
| Comenzo, RL | 1 |
| Hassoun, H | 1 |
| Kewalramani, T | 1 |
| Klimek, V | 1 |
| Dhodapkar, M | 1 |
| Reich, L | 1 |
| Teruya-Feldstein, J | 1 |
| Fleisher, M | 1 |
| Filippa, D | 1 |
| Nimer, SD | 1 |
| Sostman, HD | 1 |
| Putman, CE | 1 |
| Gamsu, G | 1 |
| Rubin, P | 1 |
| Bargon, G | 1 |
| Phillips, GL | 3 |
| Fay, JW | 1 |
| Herzig, GP | 2 |
| Herzig, RH | 1 |
| Weiner, RS | 1 |
| Wolff, SN | 2 |
| Lazarus, HM | 1 |
| Karanes, C | 1 |
| Ross, WE | 1 |
| Kramer, BS | 1 |
| Cohen, MH | 1 |
| Matthews, MJ | 1 |
| DiBella, NJ | 1 |
| Garfield, D | 1 |
| Fink, K | 1 |
| Anderson, P | 1 |
| Speer, J | 1 |
| Murphy, J | 1 |
| Mitsudo, SM | 1 |
| Greenwald, ES | 1 |
| Banerji, B | 1 |
| Koss, LG | 1 |
| Aronin, PA | 1 |
| Mahaley, MS | 1 |
| Rudnick, SA | 1 |
| Dudka, L | 1 |
| Donohue, JF | 1 |
| Selker, RG | 1 |
| Moore, P | 1 |
| Reece, DE | 1 |
| Kalaycioglu, M | 1 |
| Kavuru, M | 1 |
| Tuason, L | 1 |
| Bolwell, B | 1 |
| Jones, RB | 1 |
| Matthes, S | 1 |
| Shpall, EJ | 1 |
| Fisher, JH | 1 |
| Stemmer, SM | 1 |
| Dufton, C | 1 |
| Stephens, JK | 1 |
| Bearman, SI | 1 |
| Leeder, RG | 1 |
| Rafeiro, E | 1 |
| Brien, JF | 1 |
| Mandin, CC | 1 |
| Massey, TE | 1 |
| Chap, L | 1 |
| Shpiner, R | 1 |
| Levine, M | 1 |
| Norton, L | 1 |
| Lill, M | 1 |
| Glaspy, J | 1 |
| Alessandrino, EP | 1 |
| Bernasconi, P | 1 |
| Colombo, A | 1 |
| Caldera, D | 1 |
| Martinelli, G | 1 |
| Vitulo, P | 1 |
| Malcovati, L | 1 |
| Nascimbene, C | 1 |
| Varettoni, M | 1 |
| Volpini, E | 1 |
| Klersy, C | 1 |
| Bernasconi, C | 1 |
| Cao, TM | 1 |
| Negrin, RS | 1 |
| Stockerl-Goldstein, KE | 1 |
| Johnston, LJ | 1 |
| Shizuru, JA | 1 |
| Taylor, TL | 1 |
| Rizk, NW | 1 |
| Wong, RM | 1 |
| Blume, KG | 1 |
| Hu, WW | 1 |
| Papadakis, V | 1 |
| Dunkel, IJ | 1 |
| Cramer, LD | 1 |
| Kramer, E | 1 |
| Papadopoulos, E | 1 |
| Goldman, S | 1 |
| Packer, RJ | 1 |
| Willoughby, M | 1 |
| Baker, D | 1 |
| Garvin, J | 1 |
| Strandjord, S | 1 |
| Coccia, P | 1 |
| Kaplan, AM | 1 |
| Klemperer, M | 1 |
| Finlay, JL | 1 |
| Bellot, PA | 1 |
| Valdiserri, RO | 1 |
| Cohn, JR | 1 |
| Green, MR | 1 |
| Massin, F | 1 |
| Coudert, B | 1 |
| Foucher, P | 1 |
| Lombard, JN | 1 |
| Reybet-Degat, O | 1 |
| Jeannin, L | 1 |
| Camus, P | 1 |
| Hardwick, SJ | 2 |
| Adam, A | 2 |
| Smith, LL | 2 |
| Cohen, GM | 2 |
| White, JP | 1 |
| Ward, MJ | 1 |
| Ahmed, T | 1 |
| Ciavarella, D | 1 |
| Feldman, E | 1 |
| Ascensao, J | 1 |
| Hussain, F | 1 |
| Engelking, C | 1 |
| Gingrich, S | 1 |
| Mittelman, A | 1 |
| Coleman, M | 1 |
| Arlin, ZA | 1 |
| Wright, KC | 1 |
| Stephens, LC | 1 |
| Wallace, S | 1 |
| Savaraj, N | 1 |
| Feun, LG | 1 |
| Weinstein, AS | 1 |
| Diener-West, M | 1 |
| Nelson, DF | 1 |
| Pakuris, E | 1 |
| Tchekmedyian, NS | 1 |
| Tait, N | 1 |
| Van Echo, D | 1 |
| Aisner, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Peripheral Blood Stem Cell Transplantation (PBSCT) After Preparative Therapy Consisting of Cyclophosphamide, BCNU, and Etoposide (CBV) for Recurrent and Primarily Refractory Hodgkin's and Non-Hodgkin's Lymphoma[NCT00002941] | Phase 2 | 69 participants (Actual) | Interventional | 1998-04-30 | Completed | ||
| A Randomized Phase II Trial Comparing BeEAM With BEAM as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)[NCT02278796] | Phase 2 | 108 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for carmustine and Lung Diseases
| Article | Year |
|---|---|
Review: diagnosis of chemotherapy lung.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Busulfan; Carmustine; Cy | 1981 |
The Franz Buschke lecture: late effects of chemotherapy and radiation therapy: a new hypothesis.
Topics: Antineoplastic Agents; Bleomycin; Bone Marrow Diseases; Brain Diseases; Cardiomyopathies; Carmustine | 1984 |
Intensive therapy and autotransplantation in Hodgkin's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; C | 1994 |
[Nitrosourea-induced lung diseases].
Topics: Adult; Brain Neoplasms; Carmustine; Child; Drug Therapy, Combination; Female; Humans; Iatrogenic Dis | 1992 |
Drug-induced adverse pulmonary reactions.
Topics: Amiodarone; Asthma; Bleomycin; Carmustine; Drug-Related Side Effects and Adverse Reactions; Gold; Hu | 1985 |
High-dose, potentially myeloablative chemotherapy and autologous bone marrow transplantation for patients with advanced Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transpla | 1989 |
7 trials available for carmustine and Lung Diseases
| Article | Year |
|---|---|
Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Cyc | 2011 |
High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Blood Plate | 2003 |
How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; C | 2004 |
Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carm | 2006 |
Pulmonary toxicity of high-dose chemotherapy for breast cancer: a non-invasive approach to diagnosis and treatment.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 1997 |
Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Prescho | 2000 |
Pulmonary toxicity of carmustine in patients treated for malignant glioma.
Topics: Adult; Aged; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Dose-Response Relation | 1986 |
21 other studies available for carmustine and Lung Diseases
| Article | Year |
|---|---|
Simultaneous bilateral spontaneous pneumothorax following high-dose chemotherapy and bone marrow transplantation for mantle cell lymphoma without evidence of pulmonary disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Mo | 2010 |
[Pulmonary Langerhans histiocytosis and Hodgkin's lymphoma].
Topics: Accidents, Traffic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bronchioles; Carmusti | 2011 |
[Drug-induced changes in the lungs].
Topics: Albumins; Bleomycin; Busulfan; Carmustine; Drug-Related Side Effects and Adverse Reactions; Humans; | 1984 |
Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study.
Topics: Adolescent; Adult; Aged; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Central Nervous S | 1983 |
Chemotherapy-induced pulmonary toxicity in mice bearing L1210 leukemia.
Topics: Animals; Antineoplastic Agents; Carmustine; Cyclophosphamide; Doxorubicin; Leukemia L1210; Lung Dise | 1983 |
Combination chemotherapy with BCNU, vincristine, mitomycin-C and prednisone in refractory breast carcinoma. A pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmu | 1984 |
BCNU (1,3-bis-(2-chloroethyl)-1-nitrosurea) lung. Drug-induced pulmonary changes.
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Humans; Lung; Lung Diseases; Male; Pulmonary Fibros | 1984 |
Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors.
Topics: Adult; Analysis of Variance; Bone Marrow; Carmustine; Child; Drug Therapy, Combination; Female; Glio | 1980 |
Empiric prednisone therapy for pulmonary toxic reaction after high-dose chemotherapy containing carmustine (BCNU).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Forced Expirato | 1995 |
Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplat | 1993 |
Evaluation of reactive oxygen species involvement in amiodarone pulmonary toxicity in vivo and in vitro.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Body Weight; Carmustine; Cell Survival; Cells, Cultured | 1996 |
Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemot | 2000 |
High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 2000 |
Multiple pulmonary lesions in a patient treated with BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) for glioblastoma multiforme.
Topics: Brain Neoplasms; Carmustine; Glioblastoma; Humans; Lung Diseases; Male; Middle Aged | 1979 |
Interstitial lung disease and cancer chemotherapy.
Topics: Carmustine; Cyclophosphamide; Humans; Lung Diseases | 1979 |
Pulmonary toxicity in cancer chemotherapy.
Topics: Antineoplastic Agents; Carmustine; Female; Humans; Lung Diseases; Neoplasms; Pneumonia; Prednisone | 1979 |
A novel lung slice system with compromised antioxidant defenses.
Topics: Adenosine Triphosphate; Animals; Carmustine; Glutathione Reductase; Lung Diseases; Male; NADH Dehydr | 1990 |
Potentiation of the cell specific toxicity of paraquat by 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Implications for the heterogeneous distribution of glutathione (GSH) in rat lung.
Topics: Adenosine Triphosphate; Animals; Carmustine; Drug Synergism; Glutathione; Glutathione Reductase; Kin | 1990 |
High-dose carmustine with autologous bone marrow transplantation for the adjuvant treatment of high-grade gliomas of the central nervous system.
Topics: Adult; Aged; Astrocytoma; Bone Marrow Transplantation; Brain Diseases; Brain Neoplasms; Carmustine; | 1987 |
Experimental combination chemotherapy: intracarotid versus intravenous administration of aziridinylbenzoquinone, BCNU, and cisplatin in dogs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoqui | 1987 |
High-dose chemotherapy without autologous bone marrow transplantation in melanoma.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Di | 1986 |